Do you need SS-31 before MOTS-C? What the research shows

What did @daniellenutritionist actually say?

The creator's core argument is that you don't need SS-31 before MOTS-C, but you probably should run it first because the two peptides do different jobs. Her framing: SS-31 "repairs" mitochondria by binding to cardiolipin, while MOTS-C helps mitochondria "run more efficiently" and improves insulin sensitivity and metabolism. She also pushed back on the idea that you need high doses of SS-31 to see benefit, telling viewers that "one milligram every day" can produce good results and that working within a budget is a reasonable strategy.

She also referenced a client whose "redder" (likely referring to a continuous glucose monitor reading, or blood glucose response) improved after a MOTS-C cycle. The framing was anecdotal, which she did not clearly flag as such.

Does the science back this up?

Partially, but with significant caveats. SS-31 (also called elamipretide) does target cardiolipin, and that part is grounded in real research. MOTS-C does appear to influence metabolic signaling. But "repairs mitochondria" is doing a lot of heavy lifting as a phrase, and the sequencing claim has no clinical trial support.

SS-31 is a mitochondria-targeted antioxidant peptide that selectively binds to cardiolipin on the inner mitochondrial membrane, reducing oxidative stress and supporting membrane integrity. Szeto et al. (2014, Biochim Biophys Acta) confirmed this mechanism in animal models. However, calling this straightforward "repair" overstates what the evidence shows in humans. Most SS-31 human data comes from small trials in heart failure and kidney injury, not healthy optimization contexts.

MOTS-C is a mitochondria-derived peptide encoded in mitochondrial DNA. Lee et al. (2015, Cell Metabolism) showed it activates AMPK signaling and improves insulin sensitivity in mice. Kim et al. (2021, Nature Communications) found exercise-induced MOTS-C increases in humans, which is interesting but not the same as showing injected MOTS-C produces those same effects at clinical scale.

The sequencing claim, that SS-31 "prepares" mitochondria to get more out of MOTS-C, has no published human trial support. It is mechanistically plausible as a hypothesis, but plausible is not the same as proven.

What did they get wrong (or right)?

She got the basic mechanisms roughly right, which is more than can be said for most peptide content on TikTok. Cardiolipin binding for SS-31 is real. MOTS-C's connection to insulin sensitivity and AMPK activation is real. The idea that mitochondrial health matters before adding a metabolic stimulant is not absurd logic.

What she got wrong, or at least overclaimed: the word "repairs" is a stretch. SS-31 reduces oxidative stress and may stabilize cardiolipin interactions, but "repair" implies structural restoration that the human data does not clearly demonstrate. The sequencing protocol she recommends, SS-31 first to maximize MOTS-C benefit, is not backed by any controlled human study. It is clinical speculation dressed as established practice.

The dose discussion is also problematic. Stating that "one milligram every day" produces good results, or that she personally ran "up to four milligrams," is sharing dose information to a public audience. That crosses a line for unregulated telehealth-adjacent content, regardless of the disclaimer. There is no peer-reviewed dose-response data in healthy humans for SS-31 used this way.

What should you actually know?

Both SS-31 and MOTS-C are research peptides. Neither is FDA-approved for the wellness or optimization indications discussed in this video. SS-31 (elamipretide) is in clinical trials for rare mitochondrial diseases and heart failure. MOTS-C research in humans is at an early stage, with most evidence from animal models or small observational studies.

The sequencing claim is the kind of thing that circulates in peptide communities and gets repeated until it sounds like consensus. It is not consensus. It is a hypothesis built on mechanism, not outcome data. That does not mean it is wrong, it means it has not been tested in a way that would let us know.

If you are considering either peptide, the appropriate path is through a licensed physician who can assess your individual health status, review potential contraindications, and monitor you. A nutritionist, even a registered one, is not that person. This is not a knock on the creator's knowledge. It is a structural fact about scope of practice.

Bottom line

This video is better than average for peptide content on TikTok. The core mechanisms cited are real. But the sequencing protocol is speculative, the "repair" framing overstates the human evidence, and the dose discussion should not be public-facing. Treat this as a starting point for research, not a clinical recommendation.